XY028-133 (example 14) is a PROTAC-based CDK4/6 degrader with anti-tumor activity, extracted from patent WO2018106870A1. References: [1]. JIN, Jian， et al. COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER. Patent. US2017/065027.

纯度：≥98%

CAS：2229974-73-4